Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis

Biological therapies have dramatically improved the therapeutic landscape of psoriatic arthritis (PsA); however, 40–50% of patients are primary non-responders with response rates declining significantly with each successive biological therapy. Therefore, there is a pressing need to develop a coheren...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahmati, Sara, O’Rielly, Darren D., Li, Quan, Codner, Dianne, Dohey, Amanda, Jenkins, Kari, Jurisica, Igor, Gladman, Dafna D., Chandran, Vinod, Rahman, Proton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728744/
https://www.ncbi.nlm.nih.gov/pubmed/33303908
http://dx.doi.org/10.1038/s41598-020-78866-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728744/
https://www.ncbi.nlm.nih.gov/pubmed/33303908
http://dx.doi.org/10.1038/s41598-020-78866-2

Ejemplares similares